Abstract Number: 1042 • 2016 ACR/ARHP Annual Meeting
Four Year Imaging Outcomes in Patients with Axial Spondyloarthritis Treated with Certolizumab Pegol, Including Patients with Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis
Background/Purpose: RAPID-axSpA (NCT01087762) was a long-term study in patients (pts) with axial spondyloarthritis (axSpA) treated with certolizumab pegol (CZP). This is the first report of…Abstract Number: 1163 • 2016 ACR/ARHP Annual Meeting
Impact of E-Learning on Perceived Social Role Participation of Patients with Axial Spondyloarthritis: Results from a Longitudinal Randomized Control Trial
Background/Purpose: The purpose of this study was to Methods: Fifty-six adult patients with axSpA attending a tertiary academic spondyloarthritis clinic were randomly assigned to one…Abstract Number: 2629 • 2015 ACR/ARHP Annual Meeting
The Most Frequent Fears and Beliefs of 226 Patients with Rheumatoid Arthritis or Spondyloarthritis, Using a Novel Questionnaire
Background/Purpose: Patients with chronic inflammatory disorders such as rheumatoid arthritis (RA) or spondyloarthritis (SpA) create personal sets of fears and beliefs related to their disease.…Abstract Number: 2632 • 2015 ACR/ARHP Annual Meeting
Development and Validation of a Questionnaire Assessing the Fears and Beliefs of Patients Suffering from Chronic Rheumatic Diseases
Background/Purpose: Questionnaires assessing the beliefs of patients with chronic rheumatic diseases mainly focus on medications.1A validated questionnaire evaluating patients' fears and beliefs towards their disease…Abstract Number: 346 • 2015 ACR/ARHP Annual Meeting
Autoantibodies to Osteoprotegerin Are Independently Associated with Low Hip Bone Mineral Density and Increased Fractures in Axial Spondyloarthritis
Background/Purpose: Axial spondyloarthritis (axSpA) is associated with osteoporosis. However the underlying causes are incompletely understood. Osteoprotegerin (OPG) is a bone protective protein that acts as…Abstract Number: 2812 • 2015 ACR/ARHP Annual Meeting
Cytokine Secretion By Peripheral Blood Mononuclear Cells in Patients with Axial Spondyloarthritis and the Effect of Thymoquinone on Cytokine Profile
Background/Purpose: Axial spondyloarthritis (axSpA) defines a group of chronic inflammatory diseases which includes non-radiographic axSpA (nr-axSpA) who do not have definite sacroiliitis on pelvic X-rays.…Abstract Number: 663 • 2015 ACR/ARHP Annual Meeting
Mases Correlates Linearly with Disease Activity and Patient Related Outcomes in Patients with Axial Spondyloarthritis within the Scqm Cohort
Background/Purpose: Enthesitis is one of the potential extra-axial manifestations found in patients with spondyloarthritis (SpA). Enthesitis can be quantified using the MASES (Maastrich Ankylosing Spondylitis…Abstract Number: 2876 • 2015 ACR/ARHP Annual Meeting
Baseline Demographic and Disease Characteristics Associated with Response to Golimumab in Patients with Active Nonradiographic Axial Spondyloarthritis
Background/Purpose: Subgroup analyses can be used to investigate the size and direction of treatment effects across a range of demographic and disease characteristics. The purpose…Abstract Number: 691 • 2015 ACR/ARHP Annual Meeting
Standards for the Classification of Non-Radiographic Axial Spondyloarthritis: A European Real World Study
Background/Purpose: Classification of non-radiographic axial spondyloarthritis (nr-axSpA) requires the presence of Assessment of Spondyloarthritis international Society (ASAS) criteria for AxSpA, without radiologic evidence of sacroiliitis…Abstract Number: 2878 • 2015 ACR/ARHP Annual Meeting
Treating Axial Spondyloarthritis to Target: Influence of the Population Characteristics and Comorbidities in Reaching Ankylosing Spondylitis Disease Activity Score (ASDAS) Inactive Disease in a Cohort of Patients Treated with Tnfalpha Inhibitors Agents
Background/Purpose: The treat to target strategy (T2T), aiming at inactive disease (ID), has become the recommended approach also in the field of axial-SpA (axSpA) (1). …Abstract Number: 696 • 2015 ACR/ARHP Annual Meeting
Current and Past Smoking Are Associated with Functional Impairement and Increased Disease Activity in Axial Spondyloarthritis: Systematic Review and Meta-Analysis
Background/Purpose: The influence of smoking on the development of rheumatoid arthritis, the severity of the disease and the response to treatment is well established. The…Abstract Number: 2885 • 2015 ACR/ARHP Annual Meeting
Long-Term Effects of Etanercept on Patient-Reported Outcomes in Early Non-Radiographic Axial Spondyloarthritis: 104-Week Results of a Phase III Study
Background/Purpose: In patients with active, NSAID-resistant, non-radiographic axial spondyloarthritis (nr-axSpA) who participated in the multiphase, randomized, placebo (PBO)-controlled EMBARK study (ClinicalTrials.gov identifier: NCT01258738), health-related quality-of-life…Abstract Number: 697 • 2015 ACR/ARHP Annual Meeting
Identification Methods for Axial Spondyloarthritis in American Veterans
Background/Purpose: Current methods for identifying people with axial spondyloarthritis (AxSpA) in large datasets are inadequate because billing codes for most types of spondyloarthrtis (SpA) do…Abstract Number: 2893 • 2015 ACR/ARHP Annual Meeting
Quality of Life in Patients with Active Nonradiographic Axial Spondyloarthritis after 16 Weeks of Golimumab Treatment
Background/Purpose: Chronic inflammation, back pain, and progressive spinal stiffness associated with axial spondyloarthritis (axSpA) can decrease quality of life (QoL). The purpose of this study…Abstract Number: 709 • 2015 ACR/ARHP Annual Meeting
Progression of Patients with Non-Radiographic Axial Spondyloarthritis to Ankylosing Spondylitis: A Population-Based Cohort Study
Background/Purpose: The long-term outcome of patients with non-radiographic axial spondyloarthritis (nr-axSpA) is unclear, particularly whether few or most progress to ankylosing spondylitis (AS). Our objective…
- « Previous Page
- 1
- …
- 11
- 12
- 13
- 14
- 15
- 16
- Next Page »